Slide Deck for Neurologists: Presentation Templates for Complex Neurological Conditions

Neurological diagnoses are among the most frightening a patient can receive. Multiple sclerosis, epilepsy, Parkinson's disease, stroke — each carries enormous implications for identity, independence, and daily function. The way a neurologist communicates these diagnoses and their treatment options shapes how patients cope, how they adhere to treatment, and how effectively they manage their condition over time. A slide deck for neurologists is a clinical tool that structures these conversations and ensures patients leave with clear, actionable information rather than fear and confusion.

Slide-deck.io is a free, browser-based presentation builder that lets neurologists and neurology practices create professional patient education decks, procedure explanations, and colleague education materials without design software or hours of formatting work.

Multiple Sclerosis: Disease Course and Treatment

MS is a heterogeneous disease with a spectrum of presentations, courses, and treatment options that have expanded dramatically in the past two decades. Patients newly diagnosed with MS need structured education delivered over multiple visits — a slide deck that can be shared and reviewed at home is invaluable.

Disease Course Types

A disease course explanation deck covers the four recognized MS phenotypes:

• Relapsing-Remitting MS (RRMS): the most common form (~85% of new diagnoses). Discrete attacks (relapses) of neurological dysfunction followed by partial or complete recovery. Typically the diagnosis at initial presentation.
• Secondary Progressive MS (SPMS): evolution from RRMS, characterized by progressive worsening between relapses and declining recovery from attacks. Transition is gradual and may not be apparent until retrospect.
• Primary Progressive MS (PPMS): progressive neurological decline from onset without relapses, affecting approximately 10–15% of patients with MS. Ocrelizumab is the only currently FDA-approved DMT with demonstrated efficacy in PPMS.
• Clinically Isolated Syndrome (CIS): a first episode of neurological symptoms lasting at least 24 hours, consistent with demyelination but not yet meeting diagnostic criteria for MS. A deck explaining the risk of conversion and when treatment is recommended reduces anxiety and improves engagement with follow-up.

Disease-Modifying Therapy Comparison: Efficacy vs. Safety

The DMT landscape is now deep enough that most patients can be matched to an appropriate therapy based on disease activity, lifestyle, risk tolerance, and family planning status. A treatment comparison deck organized by efficacy tier:

Platform Therapies (moderate efficacy)

• Interferon beta agents (IFN-β 1a IM, IFN-β 1a SC, IFN-β 1b SC, pegylated IFN-β 1a): mechanism (immunomodulation), injection site reactions, flu-like side effects and management, liver monitoring
• Glatiramer acetate: mechanism (antigen competition), injection site reactions, immediate post-injection reaction and how to distinguish it from anaphylaxis
• Dimethyl fumarate: mechanism (NRF2 pathway activation), GI side effects (take with food, titration schedule), lymphopenia monitoring
• Teriflunomide: mechanism (pyrimidine synthesis inhibition), liver monitoring, teratogenicity — the accelerated elimination protocol is essential information for any patient who might become pregnant

High-Efficacy Therapies

• Natalizumab: mechanism (anti-VLA-4, blocks CNS lymphocyte trafficking), JC virus antibody status testing and what the index means, PML risk stratification (tiers by antibody index and treatment duration), MRI monitoring schedule, infusion center logistics
• Alemtuzumab: mechanism (anti-CD52, lymphocyte depletion), the unique dosing schedule (2 years of courses), intensive monitoring protocol for 48 months, secondary autoimmunity risk (thyroid disease, ITP, nephropathy) — the monitoring burden is significant and must be explicit
• Ocrelizumab: mechanism (anti-CD20 B-cell depletion), infusion schedule, infection monitoring, PML risk (lower than natalizumab but not zero), breast cancer screening guidance, vaccine timing (give live vaccines before initiating)
• Ofatumumab: subcutaneous anti-CD20 option for patients who prefer self-administration to infusion
• Cladribine: oral, immune reconstitution mechanism, 2-year treatment with extended drug-free periods, pregnancy and contraception requirements

The "Treat to Target" Approach

Patients need to understand that the goal of treatment is not just reducing relapses — it's preventing disability accumulation. A treat-to-target education slide covers: what no evidence of disease activity (NEDA) means (no relapses, no new MRI lesions, no disability progression), what triggers a treatment switch discussion, and why proactive escalation rather than reactive step-up is supported by current evidence.

MRI Monitoring Schedule

Many patients experience significant anxiety around MRI follow-up. A slide explaining the rationale and schedule — baseline MRI after starting treatment, typically annually on stable therapy, more frequently when switching or monitoring for PML — reduces anxiety and improves adherence to surveillance.

Pregnancy Considerations

MS affects women at childbearing age more than any other neurological disease. A pregnancy and MS education deck covers: which DMTs are contraindicated in pregnancy (most; exceptions include glatiramer acetate and some interferons at lower risk), the postpartum relapse risk, breastfeeding and DMT compatibility, and pre-conception planning (accelerated elimination procedure for teriflunomide; how far in advance to discontinue specific agents before conception).

Epilepsy: Patient and Family Education

An epilepsy diagnosis affects not just the patient but their entire household and social network. A comprehensive education deck for newly diagnosed patients and their families covers:

Seizure Classification

The 2017 ILAE classification system organizes seizures by onset:

• Focal onset: arising from a network in one hemisphere (focal aware vs. focal impaired awareness vs. focal to bilateral tonic-clonic)
• Generalized onset: originating at some point within and rapidly engaging bilaterally distributed networks (absence, myoclonic, tonic-clonic, tonic, atonic)
• Unknown onset: used when onset cannot be determined

Plain language explanation matters here: "focal" replaces "partial," and the old "complex partial" terminology has been retired. Patients coming from previous providers may use outdated terminology.

Medication Options

First-generation vs. second-generation vs. third-generation antiseizure medications (ASMs) differ in tolerability, drug interactions, and teratogenicity risk — all of which matter for patient selection. A medication overview deck covers the most commonly prescribed agents, organized by seizure type:

• Focal epilepsy: carbamazepine, oxcarbazepine, lacosamide, lamotrigine, levetiracetam, zonisamide
• Generalized epilepsy: valproate (highest efficacy for generalized syndromes but significant teratogenicity — REMS program required, avoid in women of childbearing potential without extensive counseling), lamotrigine, levetiracetam, ethosuximide (absence seizures)
• For patients with intellectual disability or behavioral concerns: levetiracetam behavioral side effects (discuss proactively; vitamin B6 supplementation may reduce this), clobazam, lacosamide

Driving Laws by State

This is a critical practical slide. Include: your state's seizure-free period required before driving is permitted (varies from 3 months to 12 months across states), the physician reporting obligation in your state (not all states mandate physician reporting), the restriction on commercial driver's licenses, and what patients should do in the meantime (rideshare apps, public transportation options in your area, driving alternatives discussion without judgment).

Seizure First Aid for Family Members

Build this as a handout-format slide (large text, printable, designed to be posted):

DO:

• Stay calm
• Time the seizure
• Clear the area around the person (remove hard/sharp objects)
• Put something soft under their head
• Gently roll them on their side if not in a chair (recovery position)
• Stay with them until fully alert

DO NOT:

• Hold them down
• Put anything in their mouth
• Give water or food until fully alert

CALL 911 IF:

• First known seizure
• Seizure lasts more than 5 minutes
• Person doesn't wake up after the seizure stops
• Injury occurs during the seizure
• Seizure occurs in water
• Person is pregnant or has diabetes
• Another seizure occurs within 24 hours

Surgical Evaluation Candidacy

For patients with drug-resistant epilepsy (seizures persisting despite adequate trials of ≥2 appropriate ASMs), surgical evaluation is guideline-recommended. A surgical evaluation explanation deck covers: what the presurgical evaluation involves (video-EEG monitoring, MRI protocol for epilepsy, neuropsychological testing, PET/SPECT/MEG as indicated), what the evaluation determines (whether there is a resectable seizure focus), the range of surgical options (resection, laser interstitial thermal therapy, responsive neurostimulation, vagus nerve stimulation, corpus callosotomy), and outcomes — epilepsy surgery for mesial temporal lobe epilepsy offers 60–80% chance of seizure freedom.

Parkinson's Disease: Management Deck

Motor and Non-Motor Symptoms

Parkinson's is commonly understood as a motor disease, but the non-motor burden is often what most affects quality of life. A comprehensive symptom overview slide covers: motor symptoms (resting tremor, bradykinesia, rigidity, postural instability — the "TRAP" acronym), and non-motor symptoms (cognitive impairment and dementia risk, depression and anxiety, sleep disorders including REM sleep behavior disorder, autonomic dysfunction — orthostatic hypotension, constipation, urinary urgency, anosmia as an early non-motor sign).

Medication Timing and the "On/Off" Phenomenon

For patients on levodopa/carbidopa, understanding the on/off phenomenon is essential for maximizing quality of life. A medication timing deck covers: what "wearing off" means (end-of-dose deterioration as levodopa levels fall), what "off" periods feel like (stiffness, slowed movement, tremor return, dyskinesia at peak dose as a separate phenomenon), practical strategies (consistent meal timing, low-protein meals around medication times, extended-release formulations, COMT inhibitors, MAO-B inhibitors as adjuncts), and the medication timing diary (how to track on/off periods and bring the log to the next appointment).

DBS Candidacy and What to Expect

Deep brain stimulation is one of the most effective interventions for motor fluctuations in Parkinson's disease. A DBS education deck covers: who is a candidate (significant motor fluctuations or dyskinesia, good response to levodopa, absence of dementia, adequate neuropsychological and cognitive baseline), the targets (subthalamic nucleus vs. globus pallidus interna — trade-offs), the surgical procedure (staged in most centers: lead placement, battery implant), programming (multiple sessions required after implant), realistic expectations (DBS treats motor fluctuations; it does not slow disease progression; non-motor symptoms may not respond), and battery longevity and replacement.

Migraine: Prevention and Acute Treatment

Preventive vs. Abortive Treatment

Many patients who would benefit from migraine preventive therapy don't receive it because they don't understand the distinction. A migraine treatment overview covers: acute/abortive treatment (triptans, gepants, CGRP antagonists — for use at attack onset), preventive/prophylactic treatment (for patients with ≥4 headache days per month with significant disability, or ≥8 headache days per month regardless of disability), and the importance of limiting acute medication use to ≤10–15 days per month (medication overuse headache risk).

CGRP Pathway Treatments

The CGRP revolution has transformed migraine care. A CGRP-targeted therapy deck covers: the mechanism (CGRP's role in neurogenic inflammation and vasodilation), the available options (monthly or quarterly injectable monoclonal antibodies — erenumab, fremanezumab, galcanezumab, eptinezumab IV; oral gepants for both prevention and acute treatment — atogepant, rimegepant), the expected response timeline (typically 1–3 months), and what to measure (headache diary, MIDAS or HIT-6 score comparison pre/post).

Trigger Identification

A trigger identification slide and diary instruction covers: common triggers (sleep disruption, skipped meals, caffeine withdrawal, alcohol, hormonal fluctuations in women, weather changes, strong sensory stimuli), how to use a headache diary to identify personal triggers (distinguish correlation from causation — not every trigger is present every attack), and the distinction between triggers and causes (migraine is a neurological disorder; triggers lower the threshold for an attack in a brain predisposed to migraine).

Stroke: FAST Acronym and Secondary Prevention

FAST Slide

F — Face drooping. Ask the person to smile. Is one side of the face drooping? A — Arm weakness. Ask them to raise both arms. Does one arm drift downward? S — Speech difficulty. Ask them to repeat a simple phrase. Is speech slurred or strange? T — Time to call 911. If any of these are present, call 911 immediately. Note the time symptoms started.

This slide should be designed for maximum visual impact — large type, simple icons, high contrast. It is the most important piece of public health education in neurology.

TPA Eligibility Window

For patients who have had a TIA or minor stroke and are seen in follow-up, a secondary prevention deck covers: the 4.5-hour tPA eligibility window for ischemic stroke (and when thrombectomy extends the window for large vessel occlusion), why rapid response matters ("time is brain" — approximately 1.9 million neurons die per minute during ischemic stroke), warning signs of TIA and why TIA is a medical emergency not a "mini-stroke to be watched."

Referring Physician Education

A stroke recognition deck for primary care, emergency medicine, and neurology trainees covers: the NIH Stroke Scale and its key domains, imaging (CT vs. MRI in the acute setting — what each shows and when each is indicated), the stroke code activation pathway at your institution, and teleneurology resources for rural and community hospitals.

Building Neurology Presentations on slide-deck.io

Slide-deck.io is free, browser-based, and built for the complexity that neurology demands. Embed MRI images in MS monitoring decks, seizure EEG tracings in epilepsy consent presentations, and medication comparison tables in DMT choice discussions. Share via link so patients can review the deck with family members before their next appointment — particularly important in neurology, where cognitive symptoms may affect retention.

In neurology, what patients understand about their diagnosis shapes what happens to them. Build presentations that make sure they understand enough to partner effectively in their own care.